IDRx Looks To Challenge Standard-Of-Care Sunitinib In Second-Line GIST

 
• By Alaric DeArment
  
Generate a summary of this article
Listen to this article
Beta

The company raised $120m in a series B funding round and plans to start a Phase III study of IDRX-42 next year. Scrip talked to IDRx’s execs about the company’s development strategy.

• Source: Shutterstock

IDRx, Inc is hoping to use its latest round of venture capital funding to advance its drug IDRX-42 to tackle a sarcoma subtype, gastrointestinal stromal tumor (GIST), that remains underserved despite targeted therapies being available for many years.

Key Takeaways

  • IDRx raised $120m in a series B round that it plans to use to advance its lead candidate, IDRX-42, into a pivotal trial next year.

The Plymouth, MA-based company said 7 August that it had raised $120m in a series B funding around to finance...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Financing

India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.

Scrip-Business (Free-1): Top-Selling Drugs 2024: Keytruda, Ozempic And Dupixent Dominate

 
• By Nabil

Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.

Sponsored By

Nancy Tests SPARC-931 Part 8

This is a short description. This is a short description.

spo

Akash test for clone

Test article to check the clone issue

More from Business

How A New Healthcare Dialogue Is Driving Market Access In Mexico

Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.